Garni Barkhoudarian1, Aaron R Cutler2, Sam Yost3, Bjorn Lobo4, Amalia Eisenberg4, Daniel F Kelly4. 1. Pacific Brain Tumor Center and Pituitary Disorders Program, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA, USA. barkhoudariang@jwci.org. 2. Inland Neurosurgery Institute, Pomona, CA, USA. 3. Wayne State Medical School, Detroit, MI, USA. 4. Pacific Brain Tumor Center and Pituitary Disorders Program, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA, USA.
Abstract
OBJECTIVE: With the resection of pituitary lesions, the anterior pituitary gland often obstructs transsphenoidal access to the lesion. In such cases, a gland incision and/or partial gland resection may be required to obtain adequate exposure. We investigate this technique and determine the associated risk of post-operative hypopituitarism. METHODS: All patients who underwent surgical resection of a pituitary adenoma or Rathke cleft cyst (RCC) between July 2007 and January 2013 were analyzed for pre- and post-operative hormone function. The cohort of patients with gland incision/resection were compared to a case-matched control cohort of pituitary surgery patients. Total hypophysectomy patients were excluded from outcome analysis. RESULTS: Of 372 operations over this period, an anterior pituitary gland incision or partial gland resection was performed in 79 cases (21.2 %). These include 53 gland incisions, 12 partial hemi-hypophysectomies and 14 resections of thinned/attenuated anterior gland. Diagnoses included 64 adenomas and 15 RCCs. New permanent hypopituitarism occurred in three patients (3.8 %), including permanent DI (3) and growth hormone deficiency (1). There was no significant difference in the rate of worsening gland dysfunction nor gain of function. Compared to a control cohort, there was a significantly lower incidence of transient DI (1.25 vs. 11.1 %, p = 0.009) but no significant difference in permanent DI (3.8 vs. 4.0 %) in the gland incision group. CONCLUSION: Selective gland incisions and gland resections were performed in over 20 % of our cases. This technique appears to minimize traction on compressed normal pituitary gland during removal of large lesions and facilitates better visualization and removal of cysts, microadenomas and macroadenomas.
OBJECTIVE: With the resection of pituitary lesions, the anterior pituitary gland often obstructs transsphenoidal access to the lesion. In such cases, a gland incision and/or partial gland resection may be required to obtain adequate exposure. We investigate this technique and determine the associated risk of post-operative hypopituitarism. METHODS: All patients who underwent surgical resection of a pituitary adenoma or Rathke cleft cyst (RCC) between July 2007 and January 2013 were analyzed for pre- and post-operative hormone function. The cohort of patients with gland incision/resection were compared to a case-matched control cohort of pituitary surgery patients. Total hypophysectomy patients were excluded from outcome analysis. RESULTS: Of 372 operations over this period, an anterior pituitary gland incision or partial gland resection was performed in 79 cases (21.2 %). These include 53 gland incisions, 12 partial hemi-hypophysectomies and 14 resections of thinned/attenuated anterior gland. Diagnoses included 64 adenomas and 15 RCCs. New permanent hypopituitarism occurred in three patients (3.8 %), including permanent DI (3) and growth hormone deficiency (1). There was no significant difference in the rate of worsening gland dysfunction nor gain of function. Compared to a control cohort, there was a significantly lower incidence of transient DI (1.25 vs. 11.1 %, p = 0.009) but no significant difference in permanent DI (3.8 vs. 4.0 %) in the gland incision group. CONCLUSION: Selective gland incisions and gland resections were performed in over 20 % of our cases. This technique appears to minimize traction on compressed normal pituitary gland during removal of large lesions and facilitates better visualization and removal of cysts, microadenomas and macroadenomas.
Authors: Jackson A Gondim; Joao Paulo C Almeida; Lucas Alverne F Albuquerque; Michele Schops; Erika Gomes; Tania Ferraz; Wladia Sobreira; Meissa T Kretzmann Journal: Pituitary Date: 2011-06 Impact factor: 4.107
Authors: Ronald J Benveniste; Wesley A King; Jane Walsh; Jacob S Lee; Bradley N Delman; Kalmon D Post Journal: J Neurosurg Date: 2005-06 Impact factor: 5.115
Authors: Jay Jagannathan; Rene Smith; Hetty L DeVroom; Alexander O Vortmeyer; Constantine A Stratakis; Lynnette K Nieman; Edward H Oldfield Journal: J Neurosurg Date: 2009-09 Impact factor: 5.115
Authors: Nasrin Fatemi; Joshua R Dusick; Carlos Mattozo; David L McArthur; Pejman Cohan; John Boscardin; Christina Wang; Ronald S Swerdloff; Daniel F Kelly Journal: Neurosurgery Date: 2008-10 Impact factor: 4.654
Authors: D R McCance; D S Gordon; T F Fannin; D R Hadden; L Kennedy; B Sheridan; A B Atkinson Journal: Clin Endocrinol (Oxf) Date: 1993-01 Impact factor: 3.478
Authors: James Barger; Matthew Siow; Michael Kader; Katherine Phillips; Girish Fatterpekar; David Kleinberg; David Zagzag; Chandranath Sen; John G Golfinos; Richard Lebowitz; Dimitris G Placantonakis Journal: Surg Neurol Int Date: 2018-02-14
Authors: Regin Jay Mallari; Jai Deep Thakur; Garni Barkhoudarian; Amy Eisenberg; Amanda Rodriguez; Sarah Rettinger; Pejman Cohan; Lynnette Nieman; Daniel F Kelly Journal: J Clin Endocrinol Metab Date: 2022-01-01 Impact factor: 5.958
Authors: Jai Deep Thakur; Alex Corlin; Regin Jay Mallari; Samantha Yawitz; Amalia Eisenberg; Walavan Sivakumar; Chester Griffiths; Ricardo L Carrau; Sarah Rettinger; Pejman Cohan; Howard Krauss; Katherine A Araque; Garni Barkhoudarian; Daniel F Kelly Journal: Pituitary Date: 2021-07-02 Impact factor: 4.107